@prefix this: <http://purl.org/np/RATgYbpNYnktiU1M5OCbD8mT1KGMYTl3GtUUZ_9HMdPOg> .
@prefix sub: <http://purl.org/np/RATgYbpNYnktiU1M5OCbD8mT1KGMYTl3GtUUZ_9HMdPOg#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix orcid: <https://orcid.org/> .
@prefix nkg: <https://w3id.org/neurodkg/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.bioontology.org/ontology/MEDDRA/10021750> schema:possibleTreatment sub:medtherapy .
  
  sub:medtherapy prov:wasDerivedFrom sub:quote;
    schema:drug <http://identifiers.org/drugbank/DB01080>;
    schema:targetPopulation sub:targetpop;
    nkg:indicationType nkg:SymptomaticReliefIndication .
  
  sub:quote prov:value "Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss";
    prov:wasQuotedFrom <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b8fb137-848b-45fd-9107-a6db5a675360> .
  
  sub:targetpop schema:audienceType "pediatric patients with infantile spasms 1 month to 2 years of age";
    schema:requiredMaxAge "2";
    schema:requiredMinAge "0" .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "Y/yewUXixCTaxJ6eTOT7HdMWN6+gHHvr53TAC1h0fiqtqQ+k9nFOlzHIBdCBkF/HvvrEPNHB2T9bofv9xgjs7avGsEGILEPN5lt94ZF4TvWO1je+lbuPfRxa9aDXlxBZMi1qFfTWuhzHNoPq06PWugjhjttCqrPaej2+D5zvfjM=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-04-12T10:05:40.258+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RA56KBJXCfPObqVb3hNCSbbohzz02_VEW2PxnmyIQ0Hus> .
}